Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation

    David Cella, Christine de la Loge, Fatoumata Fofana et al.  August 12, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

    Philip J Mease, Richard B Warren, Nash Peter et al.  August 09, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies

    Iain B McInnes, Philip J Mease, Yoshiya Tanaka et al.  July 30, 2024
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials

    Brown A. Matthew, Rudwaleit Martin, Floris Alexander van Gaalen et al.  July 08, 2024
    phase 4/RWE

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies

    Edward Faught, Hervé Besson, Wendyl D'Souza et al.  July 05, 2024
    None
    View

    Overview of acute seizure management in US nursing homes

    Rebecca O'Dwyer, Ilo E Leppik, Pam Eads et al.  July 02, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis

    Maksymowych P. Walter, Howard Thom , Mørup Michael Frank et al.  June 25, 2024
    phase 3

    FINTEPLA® (fenfluramine)

    Dravet Syndrome, Lennox-Gastaut Syndrome
    View

    Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies

    Antonio Gil-Nagel, J Helen Cross, Orrin Devinsky et al.  June 21, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Hidradenitis Suppurativa
    View

    Efficacy and safety of Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II):  two 48-week, randomized, double-blind, placebo-controlled, multicenter phase 3 trials.

    Alexa B Kimball, Gregor B E Jemec, Christopher J Sayed et al.  June 08, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies

    Dubreuil Maureen, Navarro-Compán Victoria, Boonen Annelies et al.  June 04, 2024